News | March 26, 2010

Genetic Testing Reveals Predisposition to Heart Disease

March 24, 2010 — Several genes are associated with heart disease, stroke, and high blood pressure, and can determine whether people may have predisposition to these conditions, according to genetics research.

In 2009, in one of the largest studies of its kind, researchers associated with the Myocardial Infarction Genetics Consortium uncovered nine genetic variants or mutations associated with the risk of early heart attack; including three that had not been previously identified.(1)

Research also shows that genes play a major role in determining how patients might react to medications that are commonly used to treat heart-related conditions.

For example, it’s been found that approximately 30 percent of the nearly 5 million patients taking Plavix do not metabolize the medication correctly because of genetic variations in their liver enzymes — putting them at about a 50 percent higher risk of heart attack or other cardiac issues, such as stroke.

People with the variant in the CYP2C19 gene (an occurrence found in about 30 percent of Caucasians and African-Americans, 20 percent of Hispanics, and up to 60 percent of Asians) had an approximate 32.4 percent reduction in effective plasma concentrations of Plavix and, as a result, were 3.6 times more likely to suffer heart attacks or other cardiac issues while taking the medication.

Studies on heart patients consistently have shown that poor metabolizers of Plavix might as well be taking a sugar pill than the standard Plavix dose, because their risk of heart attack and stroke is much higher than that of other Plavix users. However, most users don't know they are at risk, because they haven't been tested for the presence of the genetic variants causing decreased metabolism of Plavix.(2)

Genetic testing and reporting makes it easy for patients to discover any predispositions for diseases, including heart disease, and prescription medicine responses.

For more information:,

1. Source: 2009 Study by the Myocardial Infarction Genetics Consortium,
2. Rubin, Rita, “Genetic testing may yield personalized health treatments” USA TODAY, a division of Gannett Co., Inc. Feb. 24, 2010.

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing| March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init